Agile Therapeutics ROA 2024

Agile Therapeutics Aktienanalyse

What does Agile Therapeutics do?

Agile Therapeutics Inc is a biopharmaceutical company specializing in the development of women's products. The company was founded in 1997 and is based in Princeton, New Jersey, USA. Agile Therapeutics Inc focuses on manufacturing a unique range of women's products called the Women's Healthcare Division. These products aim to help women maintain their health and well-being by addressing their health issues and improving their quality of life. The products of Agile Therapeutics target various areas, including birth control, menstrual discomfort, and frequent infections. The company offers a variety of products to meet a wide range of needs. An important area in which Agile Therapeutics is active is birth control. The company has developed an innovative transdermal contraception system called Twirla, which is currently approved in the USA. In this system, the hormone Gestodene is absorbed through the skin, preventing pregnancy. The Twirla product is easy to use, safe, and effective. It may also offer several other benefits, such as higher tolerability compared to other contraceptive methods. Agile Therapeutics has also developed other products aimed at improving women's quality of life. This includes the product AG200-15, marketed as a treatment for severe menstrual discomfort. It is a progesterone-based transdermal system that allows for continuous dosing over several weeks, thereby reducing menstrual discomfort. Another product is AG890, marketed as a treatment for frequent vaginal infections such as yeast infections. This system aims to help women prevent or treat these infections and also aids in the prevention of recurring infections. The business model of Agile Therapeutics is based on the development and commercialization of women's products that address a significant need in society. The company enters into strategic partnerships with other companies and institutions to effectively and efficiently market its products. Agile Therapeutics also has a strong presence in research and development. Through intensive research efforts, the company has produced a range of innovative products that are in various stages of testing and trial. Agile Therapeutics works closely with the FDA (Food and Drug Administration) to ensure that its products meet all regulatory requirements. Overall, Agile Therapeutics is an innovative company specializing in the development of women's products. With its focus on the health needs of women, the company aims to improve the quality of life for women worldwide. With a wide range of products and a strong business model, Agile Therapeutics is well-positioned for a promising future. Agile Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Agile Therapeutics's Return on Assets (ROA)

Agile Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Agile Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Agile Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Agile Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Agile Therapeutics stock

What is the Return on Assets (ROA) of Agile Therapeutics this year?

The Return on Assets (ROA) of Agile Therapeutics is -1.41 undefined this year.

What was the ROA of Agile Therapeutics compared to the previous year?

The ROA of Agile Therapeutics has increased by -20.95% compared to the previous year.

What consequences do high ROA have for investors of Agile Therapeutics?

A high ROA is advantageous for investors of Agile Therapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Agile Therapeutics?

A low ROA can be unfavorable for investors of Agile Therapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Agile Therapeutics affect the company?

An increase in ROA of Agile Therapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Agile Therapeutics impact the company?

A reduction in the ROA of Agile Therapeutics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Agile Therapeutics?

Some factors that can influence the ROA of Agile Therapeutics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Agile Therapeutics important for investors?

The ROA of Agile Therapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Agile Therapeutics take to improve ROA?

To improve ROA, Agile Therapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Agile Therapeutics pay?

Over the past 12 months, Agile Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Agile Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Agile Therapeutics?

The current dividend yield of Agile Therapeutics is .

When does Agile Therapeutics pay dividends?

Agile Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Agile Therapeutics?

Agile Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Agile Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Agile Therapeutics located?

Agile Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Agile Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Agile Therapeutics from 12/24/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/24/2024.

When did Agile Therapeutics pay the last dividend?

The last dividend was paid out on 12/24/2024.

What was the dividend of Agile Therapeutics in the year 2023?

In the year 2023, Agile Therapeutics distributed 0 USD as dividends.

In which currency does Agile Therapeutics pay out the dividend?

The dividends of Agile Therapeutics are distributed in USD.